ME02751B - Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline - Google Patents
Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiselineInfo
- Publication number
- ME02751B ME02751B MEP-2017-27A MEP2717A ME02751B ME 02751 B ME02751 B ME 02751B ME P2717 A MEP2717 A ME P2717A ME 02751 B ME02751 B ME 02751B
- Authority
- ME
- Montenegro
- Prior art keywords
- acid derivatives
- oleanolic acid
- antioxidant inflammation
- inflammation modulators
- homologated oleanolic
- Prior art date
Links
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4636608P | 2008-04-18 | 2008-04-18 | |
US11129408P | 2008-11-04 | 2008-11-04 | |
EP09732769.6A EP2271658B1 (en) | 2008-04-18 | 2009-04-20 | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
PCT/US2009/041176 WO2009129548A1 (en) | 2008-04-18 | 2009-04-20 | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ME02751B true ME02751B (me) | 2018-01-20 |
Family
ID=40852224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2017-27A ME02751B (me) | 2008-04-18 | 2009-04-20 | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
Country Status (28)
Country | Link |
---|---|
US (3) | US7943778B2 (me) |
EP (1) | EP2271658B1 (me) |
JP (2) | JP5588966B2 (me) |
KR (2) | KR101782020B1 (me) |
CN (2) | CN102066398B (me) |
AU (2) | AU2009237581C1 (me) |
BR (1) | BRPI0911422B8 (me) |
CA (1) | CA2721666C (me) |
CO (1) | CO6311107A2 (me) |
CY (1) | CY1118475T1 (me) |
DK (1) | DK2271658T3 (me) |
EA (1) | EA020156B1 (me) |
ES (1) | ES2613964T3 (me) |
HK (2) | HK1152713A1 (me) |
HR (1) | HRP20170102T1 (me) |
HU (1) | HUE033288T2 (me) |
IL (1) | IL208759B (me) |
LT (1) | LT2271658T (me) |
ME (1) | ME02751B (me) |
MX (1) | MX2010011439A (me) |
NZ (1) | NZ588711A (me) |
PL (1) | PL2271658T3 (me) |
PT (1) | PT2271658T (me) |
RS (1) | RS55631B1 (me) |
SI (1) | SI2271658T1 (me) |
TW (1) | TWI584808B (me) |
WO (1) | WO2009129548A1 (me) |
ZA (1) | ZA201007589B (me) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
KR101354828B1 (ko) | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | mTOR 저해자, 헤르셉틴, 및/또는 HKI-272의항신생물성 조합 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP3492077A1 (en) | 2008-01-11 | 2019-06-05 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
LT2276493T (lt) | 2008-04-18 | 2019-01-10 | Reata Pharmaceuticals, Inc. | Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17 |
BRPI0911105B1 (pt) | 2008-04-18 | 2022-11-08 | Reata Pharmaceuticals, Inc | Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos |
EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
DK2271658T3 (en) * | 2008-04-18 | 2017-02-06 | Reata Pharmaceuticals Inc | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
AU2009274037B2 (en) * | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
HUE032958T2 (hu) | 2008-08-04 | 2017-11-28 | Wyeth Llc | 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi |
LT3000467T (lt) | 2009-04-06 | 2023-04-11 | Wyeth Llc | Krūties vėžio gydymo schema naudojant neratinibą |
MY163031A (en) | 2010-04-12 | 2017-07-31 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
WO2011153315A1 (en) * | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
US8802661B2 (en) * | 2010-06-04 | 2014-08-12 | Bristol-Myers Squibb Company | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors |
ES2653717T3 (es) | 2010-12-17 | 2018-02-08 | Reata Pharmaceuticals, Inc. | Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación |
EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
CA2869783C (en) | 2012-04-27 | 2022-06-21 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
CA2882418C (en) * | 2012-09-10 | 2021-05-04 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
CA2884400A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
LT2892911T (lt) * | 2012-09-10 | 2017-11-10 | Reata Pharmaceuticals, Inc. | Oleanolinės rūgšties c17 heteroarilo dariniai ir jų panaudojimo būdas |
CN102861037B (zh) * | 2012-10-26 | 2014-04-16 | 吴俊华 | Gypensapogenin B在治疗动脉粥样硬化药物中的应用 |
CN103800902A (zh) * | 2012-11-14 | 2014-05-21 | 中国药科大学 | 含有齐墩果酸的药物组合物及其医药用途 |
WO2014091467A2 (en) * | 2012-12-16 | 2014-06-19 | Mahesh Kandula | Compositions and methods for the treatment of autoimmune diseases and inflammation |
TW201514192A (zh) | 2013-03-19 | 2015-04-16 | Daiichi Sankyo Co Ltd | 萜類衍生物 |
TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
IL285832B2 (en) | 2013-08-23 | 2024-01-01 | Reata Pharmaceuticals Inc | Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs |
US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
US9896475B2 (en) | 2014-08-26 | 2018-02-20 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
JP6644433B2 (ja) | 2014-09-10 | 2020-02-12 | 第一三共株式会社 | 眼疾患治療用及び予防用徐放性医薬組成物 |
EA038328B1 (ru) | 2015-02-12 | 2021-08-10 | Рита Фармасьютикалз, Инк. | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления |
KR20180061251A (ko) | 2015-09-23 | 2018-06-07 | 리아타 파마슈티컬즈, 아이엔씨. | Il-17의 저해를 위한 c4-변형된 올레아놀산 유도체 및 다른 용도 |
KR102475130B1 (ko) * | 2016-03-31 | 2022-12-07 | (주)아모레퍼시픽 | 펜타사이클릭 트리터펜 카페익 액씨드 에스터를 포함하는 피부 보습 또는 피부 미백용 조성물 |
MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
JP7370966B2 (ja) | 2017-09-14 | 2023-10-30 | フェニックス・バイオテクノロジー・インコーポレイテッド | 神経学的状態を治療するための方法および改善された神経保護組成物 |
MX2020002883A (es) | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composiciones para tratar la infección viral. |
US10137138B1 (en) | 2018-05-29 | 2018-11-27 | King Saud University | Sulfonylurea derivatives of oleanolic acid |
EP3921327B1 (en) * | 2019-02-07 | 2023-04-05 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
CN115087660A (zh) * | 2019-12-19 | 2022-09-20 | 里亚塔医药公司 | 在c-17处具有基于氮的取代基的合成三萜类化合物及其使用方法 |
CN111205346B (zh) * | 2020-02-10 | 2022-01-28 | 中国药科大学 | 齐墩果酸的衍生物及其医药用途 |
MX2020009095A (es) | 2020-03-31 | 2022-07-28 | Phoenix Biotechnology Inc | Metodo y composiciones para el tratamiento de infeccion por coronavirus. |
EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
WO2021202720A1 (en) * | 2020-04-01 | 2021-10-07 | Fronthera U.S. Pharmaceuticals Llc | Use of triterpenoid nrf2 inhibitors |
US20230255982A1 (en) | 2020-05-09 | 2023-08-17 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
CA3204434A1 (en) | 2021-01-18 | 2022-07-21 | Xin Jiang | Synthetic ursolic acid derivatives and methods of use thereof |
CN115626947A (zh) * | 2022-09-27 | 2023-01-20 | 中山大学 | 五环三萜类天然产物的合成及其应用 |
CN115501237B (zh) * | 2022-10-27 | 2023-09-05 | 五邑大学 | 齐墩果酸衍生物在制备抑菌药物中的应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1435622A (en) | 1973-11-07 | 1976-05-12 | Biorex Laboratories Ltd | Erythrodiol derivatives |
JPS5555153U (me) | 1978-10-06 | 1980-04-14 | ||
US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
US4634208A (en) | 1983-01-31 | 1987-01-06 | Amp Incorporated | Electrical plug connector and method of terminating a cable therewith |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE3321117A1 (de) | 1983-06-10 | 1984-12-13 | Siemens AG, 1000 Berlin und 8000 München | Magnetische multipolanordnung n-ter ordnung |
ATE92499T1 (de) | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
US4635208A (en) | 1985-01-18 | 1987-01-06 | Hewlett-Packard Company | Computer-aided design of systems |
US4636308A (en) | 1985-06-13 | 1987-01-13 | Summers Don D | Method and apparatus for reclaiming drilling fluids from undesirable solids in a drilling operation |
US4636608A (en) | 1985-11-15 | 1987-01-13 | Benteler Corporation | Laser contour cut door beams |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
IL84842A0 (en) | 1986-12-24 | 1988-06-30 | Lilly Co Eli | Immunoglobulin conjugates |
ZA891076B (en) | 1988-02-16 | 1990-10-31 | Lilly Co Eli | 2',3'-dideoxy-2',2'-difluoronucleosides |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
JPH05505815A (ja) | 1990-04-04 | 1993-08-26 | ニユコメド・イメージング・アクシエセルカペト | ヌクレオシド誘導体 |
SE502569C2 (sv) | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5401838A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
UA41261C2 (uk) | 1992-06-22 | 2001-09-17 | Елі Ліллі Енд Компані | Спосіб одержання збагачених бета-аномером нуклеозидів |
YU43193A (sh) | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
DE4308042C2 (de) | 1993-03-13 | 2000-10-12 | Alstom Energy Syst Gmbh | Wälzmühle |
US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US5972703A (en) | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
DK0909184T3 (da) | 1996-07-03 | 2003-12-22 | Upjohn Co | Målrettet lægemiddelindgivelse ved anvendelse af sulfonamidderivater |
HU224918B1 (en) | 1997-01-24 | 2006-04-28 | Conpharma As | Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them |
US20050276836A1 (en) | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
US6485756B1 (en) | 1999-04-06 | 2002-11-26 | Collaborative Technologies, Inc. | Stable, homogeneous natural product extracts containing polar and apolar fractions |
DE60036101T2 (de) | 1999-05-14 | 2008-05-15 | Nereus Pharmaceuticals, Inc., San Diego | Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren |
ATE384952T1 (de) | 1999-06-25 | 2008-02-15 | Roche Diagnostics Operations | Enzymhemmungsimmunverfahren |
US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
JP2001240573A (ja) * | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
EP1322661A1 (en) | 2000-09-29 | 2003-07-02 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
CN1240102C (zh) | 2001-10-31 | 2006-02-01 | 东芝照明技术株式会社 | 灯泡形荧光灯和照明器具 |
IL161785A0 (en) | 2001-11-23 | 2005-11-20 | Chugai Pharmaceutical Co Ltd | Method for identification of tumor targeting enzymes |
EP1465615B1 (en) | 2002-01-15 | 2012-08-01 | Trustees of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
DE60325329D1 (de) | 2002-01-18 | 2009-01-29 | Univ Minnesota | Quaternäre terpensalze als biologisch aktive tenside |
WO2004064723A2 (en) | 2002-05-13 | 2004-08-05 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
US20050208151A1 (en) | 2003-10-30 | 2005-09-22 | Entelos, Inc. | Treatment of rheumatoid arthritis with FLIP antagonists |
WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
ATE357932T1 (de) | 2003-12-22 | 2007-04-15 | Alcon Inc | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
JP5087400B2 (ja) | 2004-09-07 | 2012-12-05 | パシフィック アロー リミテッド | アンゲロイル基を有する抗腫瘍化合物 |
US7714726B2 (en) | 2005-05-06 | 2010-05-11 | Dominic M. Kotab | Semi-transparent RFID tags |
JP2006347952A (ja) * | 2005-06-16 | 2006-12-28 | Yoshihiro Futamura | リパーゼ活性化作用を呈するアントラキノン誘導体、それからなる抗肥満薬、食品製剤及び化粧品 |
WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
AU2006325586B2 (en) | 2005-12-12 | 2013-01-31 | Mosamedix B.V. | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
EP1996205A2 (en) | 2006-03-23 | 2008-12-03 | Advanced Life Sciences Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
CN101117348B (zh) * | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
WO2008016095A1 (fr) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
WO2008063318A2 (en) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Betulinic acid, derivatives and analogs thereof and uses therefor |
US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
JP2010510243A (ja) | 2006-11-17 | 2010-04-02 | トラスティーズ オブ ダートマス カレッジ | 三環系−ビス−エノン(tbe)の合成および生物学的活性 |
EP2680009A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
EP3492077A1 (en) | 2008-01-11 | 2019-06-05 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
DK2271658T3 (en) | 2008-04-18 | 2017-02-06 | Reata Pharmaceuticals Inc | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES |
LT2276493T (lt) | 2008-04-18 | 2019-01-10 | Reata Pharmaceuticals, Inc. | Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17 |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
BRPI0911105B1 (pt) | 2008-04-18 | 2022-11-08 | Reata Pharmaceuticals, Inc | Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos |
EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
PT3254675T (pt) | 2009-02-13 | 2019-06-14 | Reata Pharmaceuticals Inc | Composições de dosagem oral de libertação prolongada que contêm cddo-me amorfo |
RU2401273C1 (ru) | 2009-03-30 | 2010-10-10 | Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) (статус государственного учреждения) | Противоопухолевое средство тритерпеновой природы, полученное путем модификации глицирретовой кислоты |
MY163031A (en) | 2010-04-12 | 2017-07-31 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
EP2670765B1 (en) | 2011-01-31 | 2017-10-18 | Viiv Healthcare Uk (No. 4) Limited | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
CN208692323U (zh) | 2018-08-13 | 2019-04-05 | 深圳市优维尔科技有限公司 | 一种抽吸装置 |
US11133308B2 (en) | 2019-05-03 | 2021-09-28 | International Business Machines Corporation | Uniform work function metal recess for vertical transistor complementary metal oxide semiconductor technology |
-
2009
- 2009-04-20 DK DK09732769.6T patent/DK2271658T3/en active
- 2009-04-20 KR KR1020167029864A patent/KR101782020B1/ko active IP Right Grant
- 2009-04-20 JP JP2011505260A patent/JP5588966B2/ja active Active
- 2009-04-20 WO PCT/US2009/041176 patent/WO2009129548A1/en active Application Filing
- 2009-04-20 BR BRPI0911422A patent/BRPI0911422B8/pt active IP Right Grant
- 2009-04-20 US US12/426,832 patent/US7943778B2/en active Active
- 2009-04-20 EA EA201001554A patent/EA020156B1/ru unknown
- 2009-04-20 PT PT97327696T patent/PT2271658T/pt unknown
- 2009-04-20 NZ NZ58871109A patent/NZ588711A/xx unknown
- 2009-04-20 CN CN200980123243.1A patent/CN102066398B/zh active Active
- 2009-04-20 HU HUE09732769A patent/HUE033288T2/en unknown
- 2009-04-20 SI SI200931602A patent/SI2271658T1/sl unknown
- 2009-04-20 PL PL09732769T patent/PL2271658T3/pl unknown
- 2009-04-20 ES ES09732769.6T patent/ES2613964T3/es active Active
- 2009-04-20 CN CN201410370080.XA patent/CN104250280A/zh active Pending
- 2009-04-20 EP EP09732769.6A patent/EP2271658B1/en active Active
- 2009-04-20 LT LTEP09732769.6T patent/LT2271658T/lt unknown
- 2009-04-20 ME MEP-2017-27A patent/ME02751B/me unknown
- 2009-04-20 MX MX2010011439A patent/MX2010011439A/es active IP Right Grant
- 2009-04-20 TW TW098113097A patent/TWI584808B/zh active
- 2009-04-20 KR KR20107025718A patent/KR20110010611A/ko not_active Application Discontinuation
- 2009-04-20 RS RS20170078A patent/RS55631B1/sr unknown
- 2009-04-20 CA CA2721666A patent/CA2721666C/en active Active
- 2009-04-20 AU AU2009237581A patent/AU2009237581C1/en active Active
-
2010
- 2010-10-17 IL IL208759A patent/IL208759B/en active IP Right Grant
- 2010-10-25 ZA ZA2010/07589A patent/ZA201007589B/en unknown
- 2010-11-18 CO CO10144468A patent/CO6311107A2/es active IP Right Grant
-
2011
- 2011-02-23 US US13/033,475 patent/US8394967B2/en active Active
- 2011-07-04 HK HK11106765A patent/HK1152713A1/xx unknown
-
2013
- 2013-01-14 US US13/741,072 patent/US9249089B2/en active Active
-
2014
- 2014-07-28 JP JP2014152564A patent/JP2015028019A/ja active Pending
- 2014-09-11 AU AU2014224098A patent/AU2014224098A1/en not_active Abandoned
-
2015
- 2015-05-07 HK HK15104353.6A patent/HK1203968A1/xx unknown
-
2017
- 2017-01-23 HR HRP20170102TT patent/HRP20170102T1/hr unknown
- 2017-01-23 CY CY20171100090T patent/CY1118475T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203968A1 (en) | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives :c-17 | |
HRP20182060T1 (hr) | Antioksidantni modulatori upale: derivati oleanolne kiseline s amino i drugim modifikacijama na c-17 | |
ZA201007590B (en) | Antioxidant inflammation modulators:oleanolic acid derivatives with saturation in the c-ring | |
HRP20181266T1 (hr) | Kortikosteroidni pripravci za oralnu primjenu | |
ZA201202711B (en) | Nutritional compositions for modulating inflammation including exogenous vitamin k2 | |
EP2305307A4 (en) | ANALGESIC ANTI-INFLAMMATORY PREPARATION FOR EXTERNAL APPLICATION | |
GB0604535D0 (en) | Betulonic acid derivatives | |
EP2518040A4 (en) | Low-viscosity liquid-crystal compound | |
HK1186963A1 (zh) | 含有齊墩果酸的化妝品組合物 | |
EP2475251A4 (en) | HYALURONANE / STABLE STEROID FORMULATION | |
EP2303279A4 (en) | TOPICAL STEROIDAL FORMULATIONS | |
IL206069A0 (en) | Phenyl acetic acid derivatives as inflammation modulators | |
ZA201007257B (en) | Steroid nebuliser formulation | |
GB0806802D0 (en) | Conjugated linoleic acid derivatives | |
AU2014233629B2 (en) | Orally administered corticosteroid compositions | |
GB2465746B (en) | Pharmaceutical composition for topical application | |
BRPI0911457A2 (pt) | moduladores inflamatórios antioxidantes; ácido oleanólico derivados com amina e outras modificações em c-17 | |
IL220512A0 (en) | Compositions for topical administration |